Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Vidofludimus calcium by Immunic for Primary Progressive Multiple Sclerosis (PPMS): Likelihood of Approval
Vidofludimus calcium is under clinical development by Immunic and currently in Phase II for Primary Progressive Multiple Sclerosis (PPMS). According...
Data Insights
Risk adjusted net present value: What is the current valuation of Immunic's Vidofludimus calcium?
Vidofludimus calcium is a small molecule commercialized by Immunic, with a leading Phase III program in Relapsing Remitting Multiple Sclerosis...